Pathophysiology and Role of the Gastrointestinal System in Spondyloarthritides

被引：25

作者：

Jacques, Peggy ^{[1
]}

Van Praet, Liesbet ^{[1
]}

Carron, Philippe ^{[1
]}

Van den Bosch, Filip ^{[1
]}

Elewaut, Dirk ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Rheumatol, Lab Mol Immunol & Inflammat, B-9000 Ghent, Belgium

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2012年 / 38卷 / 03期

关键词：

Pathophysiology; Inflammatory bowel disease; Ankylosing spondylitis; INFLAMMATORY-BOWEL-DISEASE; REGULATORY T-CELLS; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; ACTIVE ANKYLOSING-SPONDYLITIS; SCAVENGER RECEPTOR CD163; OPEN-LABEL TRIAL; ANTI-TNF-ALPHA; CROHNS-DISEASE; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS;

D O I：

10.1016/j.rdc.2012.08.012

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Inflammatory bowel disease (IBD) is a well-known extra-articular manifestation in spondyloarthritis (SpA); about 6.5% of patients with ankylosing spondylitis develop IBD during the course of the disease. The pathogenesis of both SpA and IBD is considered to be the result of a complex interplay between the host (genetic predisposition), the immune system and environmental factors, notably microorganisms, leading to a disturbed immune system and chronic inflammation. Over the past decade, the role of tumor necrosis factor inhibition (infliximab, etanercept, adalimumab, golimumab) in improving signs and symptoms and overall quality of life has been well documented in various forms of SpA. Future research will clarify the role of other potential targets.

引用

页码：569 / +

页数：15

共 87 条

[1]

[Anonymous], 2012, USTEKINUMAB TREATMEN

[2]

[Anonymous], 2012, CERTOLIZUMAB PEGOL S

[3]

Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response [J].